Blood tumor mutational burden (bTMB) was analyzed in patients from the EAGLE trial, a second-line trial comparing standard chemotherapy versus the anti-PDL1 durvalumab alone or versus durvalumab plus the anti-CTLA4 tremelimumab. This evidence concerns the gene CD274 and neoplasm.